Malignant lymphoma or lymphosarcoma is one of the most common tumors found in dogs these days.

The origin of these tumors can be found in the lymphoid tissues, such as lymph nodes, bone marrow, and spleen. They can arise in any tissue of the canine body.

Breeds of dogs that are believed to be more prone to lymphoma are Boxers, Bull Mastiffs, St.Bernards, Bassets, Bulldogs, Scottish Terriers and Airedale Terriers.

Lymphoma has been categorized into 5 types: mediastinal lymphoma, multi-centric, GI lymphoma, cutaneous and lymphoma of the central nervous system.

Till now, veterinarians relied on human-labeled drugs to manage lymphoma in dogs. These drugs include vincristine, prednisone, cyclophosphamide, and doxorubicin.

Now, the FDA has given a conditional approval for use of the new Tanovea-CA1 (rabacfosadine).

This is a chemotherapy drug that is supposed to be given to dogs once every 3 weeks and every dog should get 5 doses. The mechanism of action of this drug differs from the rest of the chemotherapy medication.

At the moment, the new drug is used only on patients that have already relapsed on the traditional chemotherapy and so far, they have a good clinical response.


Read the full article here: